Erin Schumaker talks with host Ruth Reader about the prospect of developing next-generation non-hallucinogenic versions of drugs such as psilocybin to treat brain disorders like depression, post-traumatic stress disorder and addiction, and the regulatory barriers that researchers who want to study psychedelics are up against.
Erin Schumaker talks with host Ruth Reader about the prospect of developing next-generation non-hallucinogenic versions of drugs such as psilocybin to treat brain disorders like depression, post-traumatic stress disorder and addiction, and the regulatory barriers that researchers who want to study psychedelics are up against.